Certara (NASDAQ:CERT) Issues FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided EPS guidance of $0.41-0.46 for the period, compared to the consensus EPS estimate of $0.43. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $388.90 million.

Certara Stock Down 7.4 %

CERT stock traded down $1.31 during mid-day trading on Wednesday, reaching $16.35. 957,631 shares of the company traded hands, compared to its average volume of 537,561. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -47.71, a P/E/G ratio of 1.81 and a beta of 1.61. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.28. Certara has a fifty-two week low of $11.81 and a fifty-two week high of $22.65. The firm’s 50 day moving average price is $17.72 and its 200 day moving average price is $16.44.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a negative net margin of 15.62% and a positive return on equity of 4.33%. The company had revenue of $88.01 million for the quarter, compared to analyst estimates of $86.80 million. As a group, equities research analysts predict that Certara will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CERT shares. Jefferies Financial Group boosted their target price on Certara from $14.00 to $15.50 and gave the stock a hold rating in a research note on Friday, March 1st. KeyCorp raised shares of Certara from a sector weight rating to an overweight rating and set a $23.00 price target on the stock in a report on Wednesday, April 10th. SVB Leerink started coverage on shares of Certara in a report on Monday, February 26th. They issued a market perform rating and a $19.00 price target on the stock. UBS Group lifted their price target on shares of Certara from $17.00 to $20.00 and gave the stock a neutral rating in a report on Friday, March 1st. Finally, Leerink Partnrs reaffirmed a market perform rating on shares of Certara in a report on Monday, February 26th. Seven analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Certara has an average rating of Hold and an average target price of $20.06.

Insider Activity

In related news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares in the company, valued at approximately $3,123,432. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the transaction, the senior vice president now directly owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Richard M. Traynor sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $18.00, for a total value of $108,000.00. Following the transaction, the senior vice president now directly owns 165,368 shares of the company’s stock, valued at approximately $2,976,624. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,427 shares of company stock valued at $405,095. Corporate insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.